Wearable Injectors and Connected Devices Conference 2019

SMi Group9 - 10 October 2019, London, UK.
SMi is proud to present the inaugural Wearable Injectors and Connected Devices Conference, taking place in London. The global wearable devices market size is expected to reach a value of $12.1 billion USD by 2021 with time dependent delivery, large volume administration with minimal injection pain and the use of connectivity to enhance user-value being key factors driving the market.

With this in mind, the conference will explore new technologies and advances of on-body devices for the administration of viscous and large molecule drug delivery, and evaluate the impact of IoT, connectivity and enhancement of user-interface, which make up core components within the wearable devices field.

Benefits of Attending

  • Listen to case studies from leading pharmaceutical companies revolutionising the medical device industry
  • Hear how on-body injectors are facilitating the administration of time-dependent, large volume and viscous drug delivery
  • Assess how connectivity is being used to improve patient adherence, health-monitoring and enhancing the user-interface
  • Explore the compatibility, pain and patient handling considerations projecting wearable devices as the future of drug delivery

Join Wearable Injectors and Connected Devices Conference 2019 in October 2019 to have the opportunity to network with Global Device Development Managers, Senior Connectivity Engineers, Leaders in Device Data Generation, Human Factors Directors and many more.

Plus two interactive pre-conference workshops

Tuesday 8th October 2019

Cross company collaboration to develop digital therapeutic solutions using connected devices

Workshop Leader: Digby Harris, Global Category Manager - Digital Therapeutics & Devices, AstraZeneca

Wearable injectors: Envisioning their evolution to address current and future unmet needs

Workshop Leader: James Blakemore, Senior Consultant, Cambridge Consultants
Workshop Leader: Sergio Marlorni, Senior Consultant, Cambridge Consultants

Who should attend?

Executives, Directors, VPs, Heads, Principals, Managers of: Drug-delivery developers, Autoinjectors, Device Engineering, Human Factor, Scientist, Product, Injectables, Packaging, Regulatory Affairs, Connectivity, Medical Device Data, Novel Product Technology, Smart device developers, Training device developers, Device-safety solution providers, Drug developers or anyone who works with Wearable Devices/ On-Body Injectors within pharmaceutical, biotech and solution providers.

To register please visit: www.wearable-injectors.co.uk/wpnwl

Early-Bird Rates

  • Book by 31st May and save £400
  • Book by 28th June and save £300
  • Book by 30th August and save £200

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Sanofi and GSK sign agreements with the Government…

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. Thom...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Scientists trace severe COVID-19 to faulty genes a…

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new resear...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

Johns Hopkins researchers publish COVID-19 'predic…

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today...

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Bayl...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...